Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Phase 2

Completed

Conditions: Diffuse, Large B-Cell, Lymphoma

Interventions: Drug: Rituximab
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2013-05-07

Last Posted Date: 2018-09-19

Lead Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Target Recruit Count: 121

Registration Number: NCT01848132

Locations: 🇪🇸
Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain
🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸
Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain

and more 18 locations

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

Not Applicable

Active, not recruiting

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)
Non Hodgkin Lymphoma (NHL)

Interventions: Drug: rituximab
Drug: prednisone
Behavioral: Geriatric Assessment

First Posted Date: 2013-04-11

Last Posted Date: 2024-05-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 201

Registration Number: NCT01829958

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

and more 5 locations

Methotrexate and Mycophenolate Mofetil for UVEITIS

Phase 3

Completed

Conditions: Uveitis

Interventions: Drug: Methotrexate
Drug: Mycophenolate mofetil
Drug: Prednisone

First Posted Date: 2013-04-11

Last Posted Date: 2024-04-02

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 216

Registration Number: NCT01829295

Locations: 🇮🇳
Aravind Eye Hospital, Pondicherry, Tamil Nadu, India
🇸🇦
King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
🇦🇺
Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia

and more 4 locations

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Bortezomib
Drug: Melphalan
Drug: Prednisone

First Posted Date: 2013-03-26

Last Posted Date: 2019-08-26

Lead Sponsor: Amgen

Target Recruit Count: 955

Registration Number: NCT01818752

Locations: 🇺🇸
California Cancer Associates for Research & Excellence, Inc. (cCARE), Fresno, California, United States
🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia

and more 209 locations

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Phase 2

Withdrawn

Conditions: Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer

Interventions: Drug: Aromatase Inhibitor
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2013-03-20

Last Posted Date: 2013-12-20

Lead Sponsor: British Columbia Cancer Agency

Registration Number: NCT01814865

Locations: 🇨🇦
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦
The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
🇨🇦
Segal Cancer Centre, Montreal, Quebec, Canada

and more 1 locations

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: ARN-509
Drug: Abiraterone acetate
Drug: Prednisone

First Posted Date: 2013-02-15

Last Posted Date: 2024-03-28

Lead Sponsor: Aragon Pharmaceuticals, Inc.

Target Recruit Count: 6

Registration Number: NCT01792687

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

Phase 3

Completed

Conditions: Giant Cell Arteritis

Interventions: Drug: Tocilizumab
Drug: Prednisone
Drug: Corticosteroids
Drug: Prednisone Placebo
Drug: Tocilizumab Placebo
Drug: Methotrexate

First Posted Date: 2013-02-13

Last Posted Date: 2020-02-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 251

Registration Number: NCT01791153

Locations: 🇺🇸
Univ of Calif., Los Angeles; Rheumatology, Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Rheumatology Assoc. of S. Florida - Clinical Research Center, Boca Raton, Florida, United States

and more 75 locations

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Drug: Bicalutamide
Drug: Abiraterone Acetate
Drug: Degarelix
Drug: Flutamide
Drug: Goserelin Acetate
Drug: Leuprolide Acetate
Drug: Nilutamide
Drug: Prednisone

First Posted Date: 2013-02-07

Last Posted Date: 2024-11-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 310

Registration Number: NCT01786265

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effect of Steroids on Thrombosis (Blood Clot Formation) and Inflammation in Patients Undergoing Hip Surgery

Not Applicable

Completed

Conditions: Total Hip Replacement

Interventions: Drug: Placebo (for Prednisone)
Drug: Prednisone
Drug: Hydrocortisone

First Posted Date: 2013-02-04

Last Posted Date: 2017-01-05

Lead Sponsor: Hospital for Special Surgery, New York

Target Recruit Count: 40

Registration Number: NCT01782859

Locations: 🇺🇸
Hospital for Special Surgery, New York, New York, United States

A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

Phase 2

Completed

Conditions: Kidney Transplantation

Interventions: Drug: ASKP1240
Drug: Tacrolimus
Drug: Mycophenolate Mofetil (MMF)
Drug: Basiliximab
Drug: Methylprednisone
Drug: Prednisone

First Posted Date: 2013-01-31

Last Posted Date: 2024-01-08

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 149

Registration Number: NCT01780844

Locations: 🇺🇸
Site US10038, Pittsburgh, Pennsylvania, United States
🇺🇸
Site US10007, Atlanta, Georgia, United States
🇺🇸
Site US10018, Chicago, Illinois, United States

and more 39 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy